It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BEAM’s FA Score shows that 1 FA rating(s) are green whileRLAY’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BEAM’s TA Score shows that 6 TA indicator(s) are bullish while RLAY’s TA Score has 7 bullish TA indicator(s).
BEAM (@Biotechnology) experienced а +3.58% price change this week, while RLAY (@Biotechnology) price change was +7.75% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.75%. For the same industry, the average monthly price growth was +7.78%, and the average quarterly price growth was +47.65%.
BEAM is expected to report earnings on Nov 10, 2025.
RLAY is expected to report earnings on Nov 05, 2025.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
BEAM | RLAY | BEAM / RLAY | |
Capitalization | 2.4B | 783M | 307% |
EBITDA | -414.33M | -338.15M | 123% |
Gain YTD | -4.315 | 10.194 | -42% |
P/E Ratio | N/A | N/A | - |
Revenue | 60.3M | 8.36M | 722% |
Total Cash | 1.15B | 657M | 175% |
Total Debt | 155M | 34.2M | 453% |
BEAM | RLAY | |
---|---|---|
RSI ODDS (%) | 1 day ago90% | 2 days ago90% |
Stochastic ODDS (%) | 1 day ago89% | 2 days ago90% |
Momentum ODDS (%) | 1 day ago76% | 2 days ago80% |
MACD ODDS (%) | 1 day ago79% | 2 days ago71% |
TrendWeek ODDS (%) | 1 day ago80% | 2 days ago78% |
TrendMonth ODDS (%) | 1 day ago79% | 2 days ago75% |
Advances ODDS (%) | 8 days ago78% | 5 days ago81% |
Declines ODDS (%) | 22 days ago85% | N/A |
BollingerBands ODDS (%) | 1 day ago90% | 2 days ago90% |
Aroon ODDS (%) | 1 day ago76% | 2 days ago72% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
DINIX | 23.82 | 0.03 | +0.13% |
BNY Mellon International Stock Index I | |||
GCTMX | 15.65 | -0.04 | -0.25% |
Goldman Sachs International T/M Eq C | |||
LGMNX | 27.03 | -0.10 | -0.37% |
Loomis Sayles Global Allocation N | |||
JGRTX | 138.99 | -0.61 | -0.44% |
Janus Henderson Enterprise S | |||
SGFFX | 53.76 | -0.59 | -1.09% |
Sparrow Growth A |
A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.
Ticker / NAME | Correlation To BEAM | 1D Price Change % | ||
---|---|---|---|---|
BEAM | 100% | -2.79% | ||
CRSP - BEAM | 67% Closely correlated | -2.16% | ||
NTLA - BEAM | 63% Loosely correlated | -1.04% | ||
RXRX - BEAM | 61% Loosely correlated | -3.41% | ||
NRIX - BEAM | 56% Loosely correlated | -2.25% | ||
SYRE - BEAM | 55% Loosely correlated | +4.77% | ||
More |
A.I.dvisor indicates that over the last year, RLAY has been loosely correlated with NRIX. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if RLAY jumps, then NRIX could also see price increases.
Ticker / NAME | Correlation To RLAY | 1D Price Change % | ||
---|---|---|---|---|
RLAY | 100% | -2.58% | ||
NRIX - RLAY | 52% Loosely correlated | -0.12% | ||
IMNM - RLAY | 52% Loosely correlated | +4.05% | ||
BDTX - RLAY | 51% Loosely correlated | +4.27% | ||
RXRX - RLAY | 50% Loosely correlated | +1.43% | ||
BEAM - RLAY | 50% Loosely correlated | +0.37% | ||
More |